Abstract library

22 results for "Tesselaar".
#2731 177Lu-DOTATATE Plus 166Ho-Radioembolization in Patients with Neuroendocrine Tumours; A Single Center, Prospective, Interventional, Non-Comparative, Open Label, Phase II Study (HEPAR PLuS Study)
Introduction: The liver is the most commonly affected organ in metastatic neuroendocrine disease and is the most incriminating factor for patient survival. Additional treatment of liver disease with radioembolization may improve outcome in NET patients with bulky residual liver disease after PRRT.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: M.D. Ph.D. Arthur Braat
Authors: Braat A, Rutger B, Van Rooij R, Braat M, ...
#2738 Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma
Introduction: Gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) is a poorly understood disease with limited treatment options. Due to its low incidence and wide tissue distribution few representative preclinical models are available
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: MD PhD Margot Tesselaar
#2748 CT-Based Radiomics for Prediction of Outcome after Somatostatin Analogues in Patients with Liver Metastases of a Neuroendocrine Tumor: An Exploratory Study
Introduction: Response evaluation and prediction of outcome of a neuroendocrine tumor (NET) remains difficult.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Femke Staal
#2796 Avelumab for Advanced Merkel Cell Carcinoma in the Netherlands; A Nationwide Survey
Introduction: Merkel cell carcinoma (MCC) is a rare, tumor of the skin associated with high recurrence rates and poor survival. Clinical trials have shown activity of checkpoint inhibitors targeting programmed death-(ligand)-1 (PD-(L)1). Avelumab is the only PD-L1 inhibitor that has been approved in the Netherlands for advanced/metastatic MCC (mMCC).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Sonja Levy
#2913 The Predictive Value of Neuroendocrine Transcript Analysis in Daily Practice: An Independent ‘Real-World’ Validation Study
Introduction: Assessment of disease status remains the fundamental basis in the management of gastro-entero-pancreatic neuro-endocrine tumors (GEPNETs). Circulating molecular information might be used as a liquid biopsy to predict its clinical course.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Mark van Treijen
#2977 Predicting Survival in Patients with a Neuroendocrine Tumor of the Small Intestine (SI-NET)
Introduction: SI-NET comprise the largest group of neuroendocrine tumors. Because of their heterogeneity, predicting survival has proven challenging. A nomogram (NG) to assess SI-NET disease specific survival (DSS) has been developed in 2010 by Modlin, et al. based on analysis of retrospective data from the Surveillance, Epidemiology and End Results (SEER) database.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Sonja Levy
Keywords: SI-NET, Nomogram, Survival
#2982 Comprehensive Molecular Analysis Identifies Driver Mutations in Metastases of Sporadic Well-Differentiated Neuroendocrine Tumours of the Small Intestine
Introduction: Small intestinal neuroendocrine tumours (SI-NETs) represent a heterogenous group of tumours. The molecular mechanisms which contribute to progression of SI-NETs are poorly elucidated. They are considered to be molecularly distinct from neuroendocrine carcinomas (NECs), which share oncogenic pathways with adenocarcinomas.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Drs Kris Samsom
#3001 Early Response Assessment for Prediction of Overall Survival after Peptide Receptor Radionuclide Therapy
Introduction: PRRT response assessment is performed using RECIST, yet functional assessment using 68Ga-DOTATATE PET/CT and plasma CgA might give additional information about prediction of overall survival (OS).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Daphne Huizing
#3042 The Use of Total Parenteral Nutrition in a Series of Patients with Neuroendocrine Tumours in United Kingdom and the Netherlands
Introduction: There are controversies about the use of total parental nutrition (TPN) in patients with cancer. Currently data regarding TPN use in patients with neuroendocrine tumours (NETs) are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Dominique Clement
#3049 Organoid Models of Neuroendocrine Cell Growth and Tumorigenesis
Introduction: A paucity of in vitro and in vivo models has limited the study of Neuroendocrine neoplasms (NENs). Moreover, little is known about normal neuroendocrine (NE) cells and how they contribute to NEN formation.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: PhD Talya Dayton